ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LY3971297

A development code. Also written as “LY3971297 IV”.

Its studies are mostly in Heart Failure · Obesity, led by Eli Lilly.

Furthest: phase 1, since Nov 20, 20232 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly21 open or runningphase 1since Nov 20, 2023Nov 20, 2023Nov 2027phase 1 · NCT07547540

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2023First study: phase 1 study in ObesityFirst studyNCT06148272 · 200 enrolled · United States, Japan, Singapore
  2. Apr 17, 2026Phase 1 study in Heart FailureNCT07547540 · 90 planned · United States, Japan, Moldova and more

Ahead

  1. Nov 2027Primary completion: phase 1 study in Heart FailureNCT07547540

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07547540Heart Failure · United States, Japan, Moldova and more1RecruitingNov 202790
NCT06148272Obesity · United States, Japan, Singapore1CompletedAug 18, 2026200

How it is read

Names in the registry

  • “LY3971297”, 3 entries
  • “LY3971297 IV”, 1 entry

Codes read as this program: LY3971297.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.